Drugs / Carimune NF Liquid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00168012 | Sep 2004 → Sep 2005 | common variable immunodeficiency, selective IgG immunodeficiency | CSL Behring | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carimune NF Liquid | “Carimune NF Liquid, a ready-to-use, high-concentration, liquid immunoglobulin preparation is safe and effective.” PMID 17479360 ↗ May 2007 |
| Modality | Protein / enzyme biologic | “Carimune NF Liquid, a ready-to-use, high-concentration, liquid immunoglobulin preparation is safe and effective.” PMID 17479360 ↗ May 2007 |
| Route | Intravenous | “received intravenous infusions of Carimune NF Liquid every 3-4 weeks for 6 months” PMID 17479360 ↗ May 2007 |